Spyre Therapeutics stock hits 52-week high at 42.93 USD
Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $42.93 USD, reflecting a 100.85% appreciation over the past year and a 131% return in six months. The company's market capitalization is now $3.95 billion, with analysts revising earnings upwards and setting price targets up to $70. This surge is fueled by accelerated clinical trial timelines for inflammatory bowel disease treatments and positive analyst ratings, although InvestingPro suggests the stock might be overvalued.
Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price
Wells Fargo & Company has increased its price target for Spyre Therapeutics (NASDAQ:SYRE) to $50 from $40, maintaining an "overweight" rating and suggesting an 18.8% upside. This positive forecast aligns with a general "Buy" consensus among analysts, with an average target price of $53.44. Despite a recent EPS miss and some insider selling, institutional investors hold a significant portion of the stock.
Spyre Therapeutics (NASDAQ:SYRE) Receives Buy Rating from BTIG Research
BTIG Research has reiterated a "buy" rating for Spyre Therapeutics (NASDAQ:SYRE) with a price target of $70.00, suggesting a potential 67.6% upside. Other analysts also generally hold a positive outlook, with an average target price of $53.88. The company's stock has shown recent upward movement, but its last quarterly earnings missed analyst estimates, and insiders have been selling shares.
Spyre Therapeutics Files For Mixed Shelf Of Up To $500 Million
Spyre Therapeutics has filed for a mixed shelf offering of up to $500 million. This move allows the company to offer various securities over time, providing flexibility for future financing needs. The filing was reported by Reuters.
Spyre Therapeutics (SYRE) Initiates Mixed Securities Shelf Filin
Spyre Therapeutics (SYRE) has filed for an automatic mixed securities shelf, enabling greater flexibility in capital raising to fund its growth initiatives. The biotechnology company, specializing in inflammatory bowel disease treatments, exhibits strong financial health with high liquidity but faces challenges with ongoing operational losses and significant insider selling. Despite a "moderate buy" analyst rating, its stock shows high volatility and a potentially overvalued P/B ratio.
Spyre Therapeutics: Q4 Earnings Snapshot
Spyre Therapeutics, Inc. reported a significant loss of $62.5 million in its fourth quarter, or 70 cents per share, missing Wall Street's expectations of a 66-cent loss per share. For the entire year, the company's loss totaled $155.2 million, equating to $1.98 per share. This financial data was compiled using information from Zacks Investment Research.
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics announced its fourth quarter and full year 2025 financial results, including $757 million in cash and an expected runway into the second half of 2028. The company is on track for six proof-of-concept readouts in 2026 across its SKYLINE and SKYWAY Phase 2 trials, targeting inflammatory bowel disease and rheumatic diseases. These trials are evaluating long-acting antibodies designed to improve efficacy and convenience for patients.
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Spyre Therapeutics recently presented new data at the 21st ECCO Congress, highlighting the differentiated profile of SPY003, an anti-IL-23 agent for IBD. The presentations included follow-up Phase 1 data for SPY003, showing quarterly or twice-yearly dosing potential and targeted biological activity. Additionally, Spyre disclosed details of its SKYLINE platform trial and preclinical data demonstrating the superior efficacy of dual-targeting TL1A and IL-23 combination therapy over monotherapies.
IBD antibodies aim for twice-yearly dosing and stronger combos in new data
Spyre Therapeutics announced scientific presentations at the 21st ECCO Congress, revealing interim 20-week Phase 1 results for SPY003 for IBD, which showed good toleration and a pharmacokinetic profile supporting quarterly or biannual dosing. The company also presented details of its SKYLINE platform trial and preclinical data indicating that a dual TL1A/IL-23 combination therapy outperformed monotherapies in mouse models. These presentations highlight Spyre's strategy to redefine IBD standard of care through long-acting antibodies and combinations.
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026
Spyre Therapeutics (SYRE) has outlined its strategic priorities for 2026, focusing on six Proof of Concept (POC) readouts. The company successfully completed enrollment for its SKYLINE ulcerative colitis trial ahead of schedule, with Part A readouts expected in Q2 2026, while the SKYWAY basket trial for other inflammatory conditions remains on track for Q4 2026 readouts. Spyre Therapeutics also reported a strong financial position with $783 million in pro forma cash as of September 2025, providing a cash runway through the second half of 2028.
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026
Spyre Therapeutics (SYRE) has outlined its 2026 plans, prioritizing six Proof-of-Concept (POC) readouts, with SPY001 enrollment for ulcerative colitis completed ahead of schedule, accelerating Part A readouts to Q2 2026. The company boasts $783 million in pro forma cash, providing a financial runway through mid-2028, and has received unanimous "Buy" ratings from analysts with a projected 66% upside. Spyre is a clinical-stage biotech developing advanced antibody therapeutics for inflammatory bowel disease, with a pipeline including SPY001, SPY002, and SPY003.
17 Biotechnology Stocks with More Than 50% Upside
This article identifies 17 biotechnology stocks with significant upside potential, focusing on Spyre Therapeutics as an example. Spyre Therapeutics is highlighted for its strong analyst sentiment, projected 66.1% upside, and pipeline advancements in inflammatory bowel disease treatments, with several key readouts anticipated in 2026. The company also boasts a solid financial runway into 2028 and a recent key executive appointment.
Spyre Therapeutics stock hits 52-week high at 35.82 USD
Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $35.82, driven by strong investor confidence, a 53.62% 1-year return, and a 100.23% gain over six months. The company has also accelerated its clinical trial timeline for inflammatory bowel disease treatments, with several proof-of-concept readouts expected by 2026. Mizuho and Jones Trading have initiated/upgraded coverage, citing promising advancements in its HLE monoclonal antibody pipeline.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, a clinical-stage biotechnology company, announced the grant of inducement stock options to five new non-executive employees. These awards, totaling 30,200 shares, were approved by the independent Compensation Committee on February 2, 2026, with an exercise price of $32.75. The vesting schedule is designed to begin one year after the employee's start date, with continuous service required.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, a clinical-stage biotechnology company, announced the grant of stock options to five non-executive employees as inducement awards. These options, approved by the Compensation Committee, are material to the employees' acceptance of employment and were granted under the company's 2018 Equity Inducement Plan. The awards are intended to help redefine the standard of care for inflammatory bowel disease and rheumatic diseases through their pioneering long-acting antibodies.
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE)
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on February 2, 2026, bringing his total holdings to 657,540 shares. This transaction is part of a pattern, as he has sold 75,000 shares over the past year with no purchases, alongside three other insider sells. The stock is currently trading at $32.8 per share, suggesting it is significantly overvalued compared to its GF Value of $2.23.
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by Brokerages
Spyre Therapeutics, Inc. (NASDAQ:SYRE) has received a consensus "Buy" rating from ten brokerages, with an average 12-month price target of $53.88. The company's shares recently opened at $31.98, trading within a 52-week range of $10.91–$35.31. Insider activity shows CEO Cameron Turtle sold 15,000 shares, reducing his position by 2.18%, while institutions and hedge funds hold about 80.4% of the stock.
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Significant Decrease in Short Interest
Spyre Therapeutics (NASDAQ:SYRE) experienced a significant decrease in short interest in January, falling by 13.5% to 10,069,741 shares. This reduction in bearish sentiment aligns with a generally bullish outlook from analysts, who currently rate the stock as a "Buy" with an average target price of $53.88. Insider activity showed CEO Cameron Turtle selling 15,000 shares in early January, though insiders still collectively own a substantial portion of the company's stock.
AlphaQuest LLC Purchases 61,989 Shares of Spyre Therapeutics, Inc. $SYRE
AlphaQuest LLC significantly increased its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) during the third quarter, purchasing 61,989 additional shares to bring its total holdings to 66,163 shares, valued at $1.109 million. This move is accompanied by generally positive analyst ratings, with a consensus "Buy" rating and a price target of $53.88 for the stock. Despite a recent sale by CEO Cameron Turtle, institutional investors and company insiders maintain substantial ownership in the clinical-stage biotechnology company.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced the grant of inducement awards in the form of stock options to Kate Chevlen, its new Chief Commercial Officer. The award of 108,155 stock options, with an exercise price of $34.09, was made in connection with her employment acceptance and will vest over four years, subject to continuous service. This is part of the company's 2018 Equity Inducement Plan.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced the grant of stock options to Kate Chevlen, their new Chief Commercial Officer, as an equity inducement award. These options cover 108,155 shares of common stock, granted on January 22, 2026, with an exercise price of $34.09. The awards are part of the company's 2018 Equity Inducement Plan and are designed to vest over time, contingent on continued employment.
Spyre’s new commercial chief granted 108K stock options at $34.09
Spyre Therapeutics has granted its new Chief Commercial Officer, Kate Chevlen, 108,155 stock options with an exercise price of $34.09 per share. These options, granted under the company's 2018 Equity Inducement Plan, have a 10-year term and a vesting schedule that begins one year after the start date. This grant is considered material to her employment acceptance, in accordance with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced that its Compensation Committee granted stock options to Kate Chevlen, the new Chief Commercial Officer. These options, for 108,155 shares of common stock, serve as an equity inducement award and were material to her acceptance of the position. The options have a 10-year term, an exercise price of $34.09, and will vest over four years, subject to her continuous employment.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced the grant of stock options to Kate Chevlen, their new Chief Commercial Officer, as an equity inducement award. These options, totaling 108,155 shares with a 10-year term and an exercise price of $34.09, will vest over four years based on continuous service. This award is material to her acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Gem With 65% Upside Potential
Spyre Therapeutics (SYRE) is a burgeoning biotech company focused on inflammatory bowel disease (IBD) treatments, with analysts projecting a 65.53% upside from its current price of $34.09. Despite being a clinical-stage company with no current revenue, its pipeline, including leading candidate SPY001, and strategic rebranding are drawing significant investor confidence. The stock is technically bullish, trading above moving averages, and is considered a promising investment for growth-oriented portfolios in the biotechnology sector.
SYRE: BTIG Reiterate Buy Rating with $70 Price Target | SYRE St
BTIG has reiterated its Buy rating for Spyre Therapeutics (SYRE) with a $70 price target, reflecting continued confidence in the company's prospects. This consistent endorsement from BTIG aligns with other recent Buy or Outperform ratings from firms like Mizuho, Citigroup, and Jones Trading. Spyre Therapeutics is a biotechnology company focused on developing treatments for inflammatory bowel disease (IBD).
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
Wall Street analysts are bullish on Spyre Therapeutics, Inc. (SYRE), giving it a consensus Strong Buy rating and a one-year average share price target of $56.67, implying a 72.77% upside. This optimism follows positive Phase 1 trial results for their IBD drug SPY003, analyst coverage from Wells Fargo and Mizuho, and a significant reduction in net loss in the third quarter. The company, which specializes in treatments for inflammatory bowel and rheumatic diseases, saw its shares surge over 69% in the past three months.
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
Wall Street analysts have a "Strong Buy" rating for Spyre Therapeutics, Inc. (SYRE), with an average one-year price target of $56.67, indicating a potential upside of 72.77%. This optimism stems from positive Phase 1 trial results for its IBD treatment SPY003, promising analyst updates including a Buy rating from Wells Fargo and an Outperform rating from Mizuho, and a significant reduction in net loss reported in the third quarter. Mizuho projects global sales for the company could reach $1.7 billion by 2035.
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating
Wall Street analysts have a "Strong Buy" rating for Spyre Therapeutics, Inc. (SYRE), with an average one-year share price target of $56.67, indicating a 72.77% upside. This optimism follows positive Phase 1 trial results for SPY003, potential in its IBD treatment pipeline, and a significant reduction in net loss in Q3. Major firms like Wells Fargo and Mizuho have reiterated Buy and Outperform ratings, respectively, highlighting the company's valuation and growth potential.
Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule
Spyre Therapeutics Inc. has completed enrollment for its SPY001 Skyline Trial in ulcerative colitis (UC) ahead of schedule. This announcement, made via Reuters, indicates significant progress in the company's clinical development program.
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% Higher - What's Next?
Spyre Therapeutics (NASDAQ:SYRE) saw its stock jump 7.7% in mid-day trading on light volume, reaching $34.04, despite trading 82% below its average session volume. Analyst sentiment is largely bullish with a "Buy" consensus rating and an average price target of $53.88, following several upgrades. The company recently reported a narrower-than-expected quarterly loss, though CEO Cameron Turtle sold a significant number of shares in November.
Spyre Therapeutics accelerates clinical trial timeline for IBD treatments By Investing.com
Spyre Therapeutics has announced it is accelerating its clinical trial timeline for inflammatory bowel disease (IBD) and rheumatic condition treatments, with six proof-of-concept readouts expected in 2026. Enrollment for its SPY001 antibody trial is ahead of schedule, with initial readouts now anticipated in Q2 2026. The company also appointed Kate Tansey Chevlen as Chief Commercial Officer and reported a pro forma cash position of $783 million, providing runway into the second half of 2028.
Spyre Therapeutics đẩy nhanh tiến độ thử nghiệm lâm sàng cho các phương pháp điều trị IBD
Spyre Therapeutics (NASDAQ:SYRE) công bố rằng họ dự kiến sẽ có sáu kết quả thử nghiệm chứng minh khái niệm trong năm 2026 từ các thử nghiệm lâm sàng SKYLINE và SKYWAY cho bệnh viêm ruột (IBD) và các bệnh lý thấp khớp. Công ty đã hoàn tất tuyển dụng bệnh nhân cho thử nghiệm kháng thể SPY001 sớm hơn dự kiến, cho phép công bố kết quả Phần A bắt đầu từ quý 2 năm 2026. Ngoài ra, Spyre đã bổ nhiệm bà Kate Tansey Chevlen làm Giám đốc Thương mại và báo cáo tình hình tiền mặt vững chắc, đủ duy trì hoạt động đến nửa cuối năm 2028.
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts
Spyre Therapeutics announced six expected proof-of-concept readouts for 2026, positioning the company for a significant year. Key highlights include the completion of the SKYLINE trial enrollment for ulcerative colitis and the SKYWAY trial being on track for readouts in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company also appointed Kate Tansey Chevlen as Chief Commercial Officer and maintains a strong financial position, with $783M in cash expected to fund operations into the second half of 2028.
Six drug trials target colitis and arthritis, with first patient data in 2026
Spyre Therapeutics (NASDAQ: SYRE) has announced a transformational 2026 with six anticipated proof-of-concept (POC) readouts from its SKYLINE Phase 2 platform in ulcerative colitis and SKYWAY Phase 2 basket trial in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company, which recently appointed Kate Tansey Chevlen as Chief Commercial Officer, also reported a strong pro forma cash balance of $783 million expected to fund operations into late 2028. This news positions Spyre for significant clinical milestones and potential late-stage development starting in 2027 for its long-acting antibody pipeline.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics has announced the grant of inducement stock options to six new non-executive employees, totaling 42,000 shares of common stock. These awards, approved by the independent Compensation Committee, were material to the employees' acceptance of employment and have an exercise price of $30.58 per share, vesting over four years. Spyre Therapeutics is a clinical-stage biotechnology company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases.
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics announced that its Compensation Committee approved inducement awards of stock options to six non-executive employees. These awards, totaling 42,000 shares, were granted under the 2018 Equity Inducement Plan with an exercise price of $30.58 and vest over time, contingent on continuous service. The grants were material to the employees' acceptance of employment, aligning with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages
MarketBeat reports that Spyre Therapeutics (NASDAQ:SYRE) has received an average "Buy" rating from eleven brokerages, with an average 12-month price target of $53.88. The company recently exceeded quarterly earnings estimates by $0.53, reporting ($0.15) EPS. Despite some insider selling, institutional investors collectively own a significant 80.39% of the stock.
Citigroup Initiates Coverage of Spyre Therapeutics (SYRE) with Buy Recommendation
Citigroup has initiated coverage of Spyre Therapeutics (SYRE) with a Buy recommendation, according to Fintel. Analysts project an average one-year price target of $53.13/share, implying a 60.74% upside from its latest closing price. Fund sentiment for SYRE is bullish, with institutional ownership increasing and a put/call ratio of 0.25.
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares
Turtle Cameron, CEO of Spyre Therapeutics (NASDAQ:SYRE), sold 15,000 shares of common stock for approximately $460,134 on January 2, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan. This comes amidst other positive developments for Spyre Therapeutics, including favorable Phase 1 results for SPY003 and a recent public offering.
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next
Spyre Therapeutics (SYRE) stock fell 2.7% as the biotech sector lagged the broader market, with investors focusing on upcoming clinical updates and a late-February quarterly report. The company, a clinical-stage developer, is working on long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with clinical readouts expected in 2026. The stock's future hinges on successful clinical execution and managing cash burn amid a challenging funding environment for early-stage biotechs.
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Spyre Therapeutics (NASDAQ: SPYR) shares fell 6.6% to $30.58 on the first trading day of 2026, closing near the lower end of its session range. Investors are focusing on the stock's ability to hold the $30 level and upcoming Phase 2 proof-of-concept data readouts expected in 2026 for its IBD and rheumatic disease therapies. The slide occurred amidst a general market reset for small-cap biotechs and shifting macro signals, including Federal Reserve comments on interest rates which particularly impact pre-revenue companies like Spyre.
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next
Spyre Therapeutics (NASDAQ: SYRE) stock dropped 7% to $30.48, underperforming broader biotech ETFs, as investors anticipate 2026 trial readouts and the next quarterly update expected in late February. The clinical-stage biotechnology company focuses on developing longer-acting antibodies for inflammatory bowel disease and other immune-mediated diseases, with upcoming Phase 2 data from its SKYLINE-UC and SKYWAY-RD studies keenly awaited by investors. The decline occurred without specific company news, suggesting broader market sentiment and risk-off positioning in small-cap biotech.
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value
Spyre Therapeutics (SYRE) recently experienced a 7.4% stock decline, highlighting the volatility of the biotech sector where it focuses on innovative treatments for inflammatory bowel disease. Despite robust financial ratios such as a 10.9 current ratio and a debt-free balance sheet, the company faces challenges including negative earnings growth, insider selling, and a low Piotroski F-Score. Valuation metrics like its 6.11 Price-to-Book ratio near a 10-year high suggest potential overvaluation, though analysts maintain a positive outlook with a target price of $52.17.
Citigroup Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Strong-Buy"
Citigroup has initiated coverage on Spyre Therapeutics (NASDAQ:SYRE) with a "buy" rating and a $64.00 price target, suggesting a potential upside of over 91%. This follows the company's Q3 earnings beat, where Spyre reported ($0.15) EPS against an estimated ($0.68). Despite a recent insider stock sale by CEO Cameron Turtle, institutional investors and hedge funds maintain a significant stake in the company.
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Mizuho
Mizuho has upgraded Spyre Therapeutics (NASDAQ:SYRE) to a "strong-buy" rating, contributing to a consensus target price of $53.88 from analysts. Shares traded up, nearing a 52-week high, despite CEO Cameron Turtle selling a portion of his holdings. The company recently reported better-than-expected quarterly earnings and is focused on developing therapeutics for inflammatory bowel disease.
Mizuho Initiates Coverage on Spyre Therapeutics (SYRE) with 'Outperform' Rating | SYRE Stock News
Mizuho has initiated coverage on Spyre Therapeutics (SYRE) with an 'Outperform' rating and a $53.00 price target, aligning with other analysts' 'Buy' ratings reflecting strong confidence in the stock. Spyre Therapeutics, a biotechnology company, focuses on developing next-generation inflammatory bowel disease (IBD) products. Despite positive analyst sentiment, GuruFocus estimates a significant downside based on its fair value calculation.
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts
Nine analysts covering Spyre Therapeutics (NASDAQ:SYRE) have issued an average "Buy" rating for the company, with a mean 1-year target price of $52.33. The company's stock opened at $33.62, has a market cap of $2.61 billion, and recently beat quarterly earnings estimates. Insider activity shows CEO Cameron Turtle selling shares, while institutional investors hold a significant portion of the stock.
Spyre Therapeutics stock hits 52-week high at 35.0 USD
Spyre Therapeutics (SYRE) stock has reached a new 52-week high of $35.00, reflecting remarkable growth with a 1-year return of 31.09%, and even higher gains over shorter periods. Despite technical indicators suggesting it may be overbought with a high Price/Book ratio of 8.99, the company continues to advance therapeutic solutions, evidenced by positive Phase 1 results for SPY003 and a recent public offering. Analyst ratings are largely positive, with price targets ranging from $21 to $70, indicating varied market expectations.
Affinity Asset Advisors LLC Raises Stock Holdings in Spyre Therapeutics, Inc. $SYRE
Affinity Asset Advisors LLC increased its stake in Spyre Therapeutics (NASDAQ:SYRE) by 26% in the second quarter, bringing their total to 606,678 shares valued at $9.08 million. Institutional investors now own approximately 80.39% of the company, which analysts have rated as a "Buy" with an average price target of $52.33. Despite CEO Cameron Turtle selling 15,000 shares, insiders still hold about 15.43% of the preclinical biotechnology firm.
